Clinical Trials

  • Almost 40,000 people get HIV in the U.S. each year and almost all occur via sexual contact, especially male-to-male contact. The number of new infections has decreased slightly each year, however, we need other HIV prevention tools, such as developing a greatly, effective HIV vaccine, to better reduce HIV infections. An HIV vaccine is the best long-term hope for ending AIDS. We are looking for healthy, 18-60 year old and HIV-negative people to join studies we conduct. SCREENING AND EDUCATION: 1.
  • Antibodies are one of the natural ways that our bodies fight or prevent infection. Were testing an antibody to find out if its safe, if they don't make people feel uncomfortable, how these study antibodies move throughout the body, and to measure antiviral activity. You cannot get HIV from the study antibody. Firstly, request to be contacted by our study team. We'll follow up by asking you to complete a brief electronic pre-screen questionnaire to find out if you meet basic study criteria.
  • The primary objective of this study is to determine if an HIV-infected donor liver (HIVD+) transplant issafe with regards to major transplant-related and HIV-related complications. This study will evaluate if receiving a liver transplant from an HIV-infected deceased liver donor is safe with regards to survival and major transplant-related and HIV-related complications compared to receiving a liver from an HIV-uninfected deceased liver donor (HIVD-).
  • The primary objective of this study is to determine if an HIV-infected donor liver (HIVD+) transplant issafe with regards to major transplant-related and HIV-related complications. This study will evaluate if receiving a liver transplant from an HIV-infected deceased liver donor is safe with regards to survival and major transplant-related and HIV-related complications compared to receiving a liver from an HIV-uninfected deceased liver donor (HIVD-).
  • Principal Investigator

    Magdalena E. Sobieszczyk, MD, MPH
    The HIV Vaccine Trials Network (HVTN) and Columbia University Irving Medical Center are doing a study to learn more about SARS-CoV-2 infection and the COVID-19 disease that it can cause. The purpose of this study is to learn more about infection with and recovery from the virus called SARS-CoV-2. Some people know this virus by the name coronavirus. It can cause the disease called COVID-19. You are being asked to take part in this study because you are age 18 or older and have recovered from COVID-19.
  • Principal Investigator

    Magdalena E. Sobieszczyk, MD, MPH
    The purpose of the study is to create a prospective observational cohort of healthcare workers to follow and test for COVID-19 antibodies over time to understand how long antibodies last in the blood after infection, and if they correlate with immunity. The other purpose is to describe psychosocial well-being during COVID-19. We want to follow you for a year with testing and questionnaires to learn answers to these questions. Please contact us for more information and thank you for your patience.
  • Antibodies are one of the natural ways that our bodies fight or prevent infection. Were testing an antibody to find out if its safe, if it doesn't make people feel uncomfortable and to find out what may be the best dose if its given by IV infusion or sub-cutaneous injection. You cannot get HIV from the Bispecific Antibody. We'll ask you to complete a brief online questionnaire at your leisure to find out if you meet basic study criteria.
  • Antibodies are one of the natural ways that our bodies fight or prevent infection. Were testing an antibody to find out if its safe, if it doesn't make people feel uncomfortable and to find out what may be the best dose if its given by IV infusion or sub-cutaneous injection. You cannot get HIV from the Bispecific Antibody. We'll ask you to complete a brief online questionnaire at your leisure to find out if you meet basic study criteria.
  • Principal Investigator

    Michael T. Yin, MD
    We are seeking volunteers who have been told by a healthcare provider that they had COVID-19 for a study to find out how coronavirus affects the body after recovery. At each visit you will be asked to complete a questionnaire, and to provide a blood and respiratory samples. You will be compensated $50 for each study visit.
  • The purpose of this research is to find out whether an experimental drug called maribivar is safe, and whether it is more effective than the medications we usually use to treat resistant CMV infections. Half of the people who choose to be part of this research study will be given maribivar, and half will be treated according to their physicians usual practice. The groups will be assigned by chance, like by a toss of a coin.The majority of people at some time in their life become infected with CMV but do not know they have it.

Pages